Institute for Quality and Efficiency in Health Care

Medications

Empagliflozin in type 2 diabetes: Added benefit not proven

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and ...

Oncology & Cancer

Dabrafenib: Also no added benefit over vemurafenib

Dabrafenib (trade name: Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma. In January 2014, in an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal ...

Medications

Safinamide in Parkinson disease: No hint of added benefit

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson ...

page 8 from 29